Keywords
Skin diseases
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To highlight and qualify the importance and benefits of treating dermatoses with immunobiologicals. Methods: This is an integrative review of a descriptive and qualitative nature, based on studies found in the databases Regional Portal of the Virtual Health Library (VHL), Scientific Electronic Library Online (SCIELO) and National Library of Medicine and the National Institute of Health (PUBMED), using the search words "immunotherapy" AND "skin diseases", and with the filter consisting of a timeline from 2016 to 2022, articles published in Portuguese and English. Results: Actinic keratosis is a dermatosis that is related to the development of squamous cell carcinoma (SCC). In this sense, it was identified that the use of calcipotriol combined with 5-Fluorouracil is a strong association as immunotherapy for the control of actinic keratosis. The use of nivolumab associated with ipilimumab or nivolumab alone had better results than ipilimumab alone. Final considerations: Individuals with dermatoses undergoing treatment with corticosteroids associated with immunobiologicals may have an improvement in the elementary skin lesion. In patients who did not respond to conventional treatment with corticosteroids and lifestyle changes, the use of immunobiologicals shows good response and regression of lesions, improving the prognosis of patients.
References
ABREU MA e BRANDÃO BJF. Imunobiológico em crianças com dermatite atópica. BWS Journal, 2021, v. 4, p. 1-8.
CAMPOS MVF e CATALANO SP. Dermatite atópica grave em adulto e a dificuldade do manejo de tratamento no Brasil. BWS Journal, 2021, 4(e210900148): 1-7.
CARVALHO VO, et al. Guia prático de atualização em dermatite atópica-Parte II: abordagem terapêutica. Posicionamento conjunto da Associação Brasileira de Alergia e Imunologia e da Sociedade Brasileira de Pediatria. Arq Asma Alerg Imunol, v. 1, n. 2, p. 157-182, 2017.
CUNNINGHAM TJ, et al. (2017). Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 127(1): 106–116. https://doi.org/10.1172/JCI89820.
FERNANDES MO, et al. Efeitos adversos do uso de imunobiológicos no tratamento da psoríase: uma revisão integrativa. Revista de Medicina, 2018, 97(5): 486-492. https://doi.org/10.11606/issn.1679-9836.v97i5p486-492.
FERREIRA JR. Judicialização da saúde: O impacto dos processos judiciais relacionados aos imunobiológicos para doenças imuno-alérgicas no orçamento de saúde do estado de Goiás. Brazilian Journal of Development, v. 7, n. 12, p. 114729-114749, 2021.
GIAVINA-BIANCHI M e GIAVINA-BIANCHI P. Eficácia e segurança do uso de dupilumabe em dois adolescentes com dermatite atópica grave. Einstein (São Paulo), 2021, 19: 1-4. http://dx.doi.org/10.31744/einstein_journal/2021rc6064.
ELIAS AF e BRANCO AFC. Avaliação clínica e anatomopatológica do prepúcio de pacientes submetidos à postectomia em hospitais no sul de Santa Catarina. Revista da Associação Médica do Rio Grande do Sul, 2020, 64(3): 397-401.
LACERDA, MKV e REIS, VDS. Tratamento de dermatite atópica com biológicos. Trabalho de Conclusão de Curso (Bacharel em Medicina) - Centro Universitário do Planalto Central Apparecido dos Santos, Gama-DF, 2021, 25f.
LARKIN J, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine, 2019, 381(16): 1535–1546. https://doi.org/10.1056/NEJMoa1910836.
MACRUZ FMM e BRANDÃO BJF. Eficácia da ciclosporina no controle da dermatite atópica. BWS Journal, 2022, 5(e220300187): 1-11.
MENDES KDS, et al. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto - Enfermagem [online]. 2008, 17(4): 758-764. https://doi.org/10.1590/S0104-07072008000400018.
REIS AP e AARESTRUP FM. Imunoterapia e imunobiológicos na dermatite atópica. Arquivos de Asmas Alergia e Imunologia, 2019, 3(2): 123-132. http://dx.doi.org/10.5935/2526-5393.20190022.
ROSENBERG AR, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI insight, 2019, 4(6): e125476. https://doi.org/10.1172/jci.insight.125476.
SIMPSON EL, et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. Journal of the American Academy of Dermatology, 2016, 4(3):491-8. https://doi.org/10.1016/j.jaad.2015.10.043.
SOUZA MT, et al. Integrative review: what is it? How to do it?. Einstein (São Paulo) [online]. 2010, 8(1): 102-106. https://doi.org/10.1590/S1679-45082010RW1134.
TEIXEIRA TA, et al. Pênfigo foliáceo endêmico refratário na adolescência: sucesso terapêutico com imunoglobulina intravenosa. Anais Brasileiros de Dermatologia [online]. 2011, 86(4): 133-136. https://doi.org/10.1590/S0365-05962011000700035.
WOLCHOK JD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2022, 40(2): 127–137. https://doi.org/10.1200/JCO.21.02229.
WOLFF PG e GELLER M. Avanços recentes no emprego de imunobiológicos nas doenças alérgicas. Brazilian Journal of Allergy and Immunology, 2014, 2(4): 132-138.
ZATTAR GA, et al. Dermatoses na infância: perfil clínico-epidemiológico dos pacientes atendidos no ambulatório de dermatologia pediátrica do Hospital Universitário da Universidade Federal de Santa Catarina. Dissertação (Bacharelado em Medicina) – Universidade Federal de Santa Catarina, Florianópolis, 2008; 49p.